A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 QT Study in Healthy Male Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
- Status
- COMPLETED
- Phase
- PHASE2
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males
- Status
- COMPLETED
- Phase
- PHASE1
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
- Status
- TERMINATED
- Phase
- PHASE1
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
- Status
- COMPLETED
- Phase
- PHASE2
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
- Status
- TERMINATED
- Phase
- PHASE1
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Pomalidomide for Chronic Graft-versus-Host Disease
- Status
- COMPLETED
- Phase
- PHASE2
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A